Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss of $0.78/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Aurinia Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
March 5, 2020 4:02 PM EST- Cash and cash equivalents totaled approximately $306 million at December 31, 2019 -
- Positive AURORA Phase 3 results with voclosporin enabling an NDA submission for the treatment of lupus nephritis (LN) by the end of the second quarter 2020 -
- Continued build out of a top-tier commercial team, highlighted by the appointment of Max Colao, Chief Commercial Officer, focused on launch activities -
- AUDREY Phase2/3 Dry Eye Study remains on-track with results anticipated during the second half of 2020 -
VICTORIA, British Columbia--(BUSINESS... More
